Clinical Trials Directory

Trials / Completed

CompletedNCT00539851

Risk Factors for Diabetes After Stem Cell Transplantation

Risk Factors for Developing Diabetes Mellitus After Allogenic Stem Cell Transplantation

Status
Completed
Phase
Study type
Observational
Enrollment
87 (actual)
Sponsor
Vanderbilt University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

This study is proposed to investigate the incidence of Post Transplant Diabetes Mellitus (PTDM) as well as associated risk factors for the development of PTDM in patients undergoing allogenic stem cell transplantation.

Detailed description

Allogenic stem cell transplantation from related or unrelated donors has been used successfully to cure patients with a variety of hematological malignancies. Graft-versus-host disease (GVHD) is an alloreactive immune phenomenon, where the activated donor T cells recognizes the recipient as being foreign and effects a cytotoxic response. GVHD occurring in the first 100 days after transplantation is termed acute GVHD and is characterized by hepatitis, dermatitis, and enteritis. High dose corticosteroids remain one of the cornerstone therapies to treat acute GVHD. However, an association between corticosteroid therapy and the development of diabetes mellitus after solid organ transplantation has become widely recognized. Similarly, post transplant diabetes mellitus (PTDM) has been increasingly noted in the allogenic stem cell transplant population, however, to date, no systematic study has been completed to identify the incidence of PTDM and associated risk factors. We propose to investigate the incidence of PTDM as well as associated risk factors for the development of PTDM in patients undergoing allogenic stem cell transplantation.

Conditions

Timeline

Start date
2005-11-01
Primary completion
2009-08-01
Completion
2010-03-01
First posted
2007-10-05
Last updated
2010-03-19

Source: ClinicalTrials.gov record NCT00539851. Inclusion in this directory is not an endorsement.